

02<sup>nd</sup> February, 2024

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub.: Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

---

---

We would like to inform that the Board has at its meeting held today approved, *inter-alia*, the following:

- 1) Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter and nine months ended on 31<sup>st</sup> December, 2023. The said financial results are enclosed herewith as **Annexure-A**.

In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter and nine months ended on 31<sup>st</sup> December, 2023. Both Standalone and Consolidated Financial Results will be available at Company’s website [www.torrentpharma.com](http://www.torrentpharma.com).

A Press Release on Financial Results which is being submitted to the media is also enclosed herewith as **Annexure-B**.

- 2) An interim dividend of ₹ 22/- (440%) per equity share of ₹ 5/- fully paid up. The dividend is expected to be paid / dispatched on or around 23<sup>rd</sup> February, 2024.

The Board of Directors acceded to the desire of Sudhir Mehta to step down as the Director of the Company while continuing as Chairman Emeritus effective from 01-Apr-24. The copy of letter received from Sudhir Mehta is enclosed herewith as **Annexure-C**.

We would further like to inform that Shailesh Haribhakti and Haigreve Khaitan will be completing their term as Independent Directors of the Company on 31<sup>st</sup> March, 2024.

The Board meeting commenced at 11:43 am and concluded at 01:35 pm.

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,

[www.torrentpharma.com](http://www.torrentpharma.com), Email : [InvestorServices@TorrentPharma.com](mailto:InvestorServices@TorrentPharma.com)



The above is for your information and record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

Encl : A/a

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,  
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com